Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
XORTX Therapeutics Inc., a late stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, pre-diabetes, insulin resistance, metabolic syndrome, diabetes, diabetic nephropathy, and infection. It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, a program to treat acute kidney injury (AKI) associated with respiratory virus infection and associated health consequences; and XRX-225, a program for treatment of type 2 diabetic nephropathy. It has a collaboration and license agreements with the Icahn School of Medicine; and a license agreement with the University of Florida Research Foundation, Inc. The company is based in Alberta Beach, Canada. more
Time Frame | XRTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 3.42% | -1.8% | -0.77% |
1-Month Return | -13.57% | -3.48% | 0.71% |
3-Month Return | -31.64% | -7.2% | 8.81% |
6-Month Return | -43.72% | -1.54% | 12.32% |
1-Year Return | -52.92% | 8.39% | 30.57% |
3-Year Return | -99.28% | 6.07% | 29.21% |
5-Year Return | 134344.44% | 44.07% | 91.95% |
10-Year Return | 67122.22% | 106.3% | 196.04% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 20.44K | 17.88K | 75.27K | 141.96K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":14.4,"profit":true},{"date":"2021-12-31","value":12.6,"profit":true},{"date":"2022-12-31","value":53.02,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | - | (20.44K) | (17.88K) | (75.27K) | (141.96K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-2043900,"profit":false},{"date":"2021-12-31","value":-1788200,"profit":false},{"date":"2022-12-31","value":-7526800,"profit":false},{"date":"2023-12-31","value":-14195887,"profit":false}] |
Gross Margin | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Operating Expenses | 565.97K | 1.30M | 2.86M | 9.86M | 4.81M | [{"date":"2019-12-31","value":5.74,"profit":true},{"date":"2020-12-31","value":13.19,"profit":true},{"date":"2021-12-31","value":29.02,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":48.72,"profit":true}] |
Operating Income | (565.97K) | (1.30M) | (4.14M) | (10.69M) | (4.81M) | [{"date":"2019-12-31","value":-56596500,"profit":false},{"date":"2020-12-31","value":-130050300,"profit":false},{"date":"2021-12-31","value":-413578062,"profit":false},{"date":"2022-12-31","value":-1068760831,"profit":false},{"date":"2023-12-31","value":-480507730,"profit":false}] |
Total Non-Operating Income/Expense | (63.61K) | (215.88K) | (378.68K) | 2.12M | 2.91M | [{"date":"2019-12-31","value":-2.19,"profit":false},{"date":"2020-12-31","value":-7.43,"profit":false},{"date":"2021-12-31","value":-13.03,"profit":false},{"date":"2022-12-31","value":73.06,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (629.58K) | (1.28M) | (1.30M) | (6.99M) | (2.15M) | [{"date":"2019-12-31","value":-62957600,"profit":false},{"date":"2020-12-31","value":-128460200,"profit":false},{"date":"2021-12-31","value":-129588712,"profit":false},{"date":"2022-12-31","value":-698888078,"profit":false},{"date":"2023-12-31","value":-215289424,"profit":false}] |
Income Taxes | 37.21K | 13.51K | 4.39K | - | (0.01) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":36.31,"profit":true},{"date":"2021-12-31","value":11.8,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (666.79K) | (1.30M) | (1.30M) | (6.99M) | (2.15M) | [{"date":"2019-12-31","value":-66679000,"profit":false},{"date":"2020-12-31","value":-129811400,"profit":false},{"date":"2021-12-31","value":-130027764,"profit":false},{"date":"2022-12-31","value":-698888078,"profit":false},{"date":"2023-12-31","value":-215289423,"profit":false}] |
Income From Continuous Operations | (629.58K) | (1.28M) | (1.65M) | (6.99M) | (2.16M) | [{"date":"2019-12-31","value":-62957600,"profit":false},{"date":"2020-12-31","value":-128460200,"profit":false},{"date":"2021-12-31","value":-165228200,"profit":false},{"date":"2022-12-31","value":-698888078,"profit":false},{"date":"2023-12-31","value":-215806500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (629.58K) | (1.28M) | (1.30M) | (6.99M) | (2.15M) | [{"date":"2019-12-31","value":-62957600,"profit":false},{"date":"2020-12-31","value":-128460200,"profit":false},{"date":"2021-12-31","value":-129588712,"profit":false},{"date":"2022-12-31","value":-698888078,"profit":false},{"date":"2023-12-31","value":-215289424,"profit":false}] |
EPS (Diluted) | (0.80) | (0.54) | - | (1.67) | - | [{"date":"2019-12-31","value":-79.69,"profit":false},{"date":"2020-12-31","value":-54.15,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":-167.4,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
XRTX | |
---|---|
Cash Ratio | 1.34 |
Current Ratio | 1.40 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
XRTX | |
---|---|
ROA (LTM) | -33.14% |
ROE (LTM) | -29.36% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
XRTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.45 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.55 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
XRTX | |
---|---|
Trailing PE | 10.50 |
Forward PE | 0.96 |
P/S (TTM) | 0.00 |
P/B | 1.79 |
Price/FCF | NM |
EV/R | 0.00 |
EV/Ebitda | 0.09 |
XORTX Therapeutics Inc (XRTX) share price today is $1.21
Yes, Indians can buy shares of XORTX Therapeutics Inc (XRTX) on Vested. To buy XORTX Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in XRTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of XORTX Therapeutics Inc (XRTX) via the Vested app. You can start investing in XORTX Therapeutics Inc (XRTX) with a minimum investment of $1.
You can invest in shares of XORTX Therapeutics Inc (XRTX) via Vested in three simple steps:
The 52-week high price of XORTX Therapeutics Inc (XRTX) is $7. The 52-week low price of XORTX Therapeutics Inc (XRTX) is $1.09.
The price-to-earnings (P/E) ratio of XORTX Therapeutics Inc (XRTX) is 10.5
The price-to-book (P/B) ratio of XORTX Therapeutics Inc (XRTX) is 1.79
The dividend yield of XORTX Therapeutics Inc (XRTX) is 0.00%
The market capitalization of XORTX Therapeutics Inc (XRTX) is $4.34M
The stock symbol (or ticker) of XORTX Therapeutics Inc is XRTX